Follow the AMEDISYS INC share price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, AMEDISYS INC has published 150 insider filings. The latest transaction was filed on 29 July 2025 (Retenue fiscale). Among the most active insiders: Ginn Scott G. Every trade is openly available.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
25 of 150 declarations
Amedisys Inc. (ticker: AMED) is a United States-based home-based healthcare company focused on home health, hospice, and higher-acuity care delivered in the patient’s home. The company is listed in the U.S. market on NYSE/NASDAQ and is headquartered in Baton Rouge, Louisiana, with an executive office in Nashville, Tennessee. Amedisys was founded in 1982 and has built its business around the structural shift toward lower-cost, more patient-friendly care settings outside the acute hospital environment. The company’s core operating model is centered on Medicare-certified care centers and a clinically integrated service portfolio. Its home health business provides skilled nursing, therapy, and related services for patients recovering from illness, injury, or surgery, or managing chronic conditions. Its hospice platform offers end-of-life care with medical, emotional, and spiritual support for patients and families. Amedisys also offers palliative care and hospital-level or skilled-nursing-type care at home through Contessa, an Amedisys company. This broader care continuum allows the group to address multiple stages of the patient journey and deepen relationships with physicians, hospitals, and payors. From a competitive standpoint, Amedisys has long been regarded as one of the established players in the U.S. home health and hospice market. The segment remains highly regulated and operationally demanding, with reimbursement dynamics—especially Medicare—playing a central role in profitability and growth. Amedisys has disclosed that a large majority of its consolidated net service revenue historically comes from Medicare, underscoring both the defensiveness of the model and its exposure to reimbursement and compliance changes. As of December 31, 2024, the company operated 347 Medicare-certified home health care centers, 164 Medicare-certified hospice care centers, and 8 admitting high-acuity care joint ventures across 38 states and the District of Columbia. Recent developments have been significant. Amedisys divested its personal care business in 2023, sharpening its strategic focus on core home health, hospice, and higher-acuity services. The most important corporate event has been its merger agreement with UnitedHealth Group, announced in June 2023 and completed in August 2025 according to SEC filings. That transaction effectively transformed Amedisys from an independent listed healthcare operator into part of a larger managed-care and healthcare-services platform. For investors, AMED is best viewed as a U.S. healthcare-at-home platform with a strong defensive profile, a Medicare-linked revenue base, and a strategic history shaped by consolidation in the home-based care industry.